Skip to Content

JavaScript has been disabled within your browser, the content or the functionality of this web page can be limited or unavailable.

There is no panel matching the key "Alert---Site-Wide"

Quick Access Links

Clinical Trials Search Results

Search for

in

Accepting Participants (9)

Showing 1-9 of 9

Sorted By:

A-Z
Z-A

Previous Next

D798EC00001: A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
main purpose is to assess efficacy and safety of volrustomig compared to observation in participants with LA-HNSCC who have not progressed after cCRT
EA3132: Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing (temporarily closed to enrollment 08-May-2024)
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
EA3191: A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features
FRNM-008: The Vallania Study: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening
This protocol is a case-control, multicenter, diagnostic study to collect blood samples to support the development of blood-based screening tests for multiple cancers.
NRG-HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-stage Oral Cavity Cancer
how well sentinel lymph node biopsy works & compares sentinel lymph node biopsy surgery to standard neck dissection as part of the treatment for early-stage oral cavity cancer
Takeda_CP-MVC-101-01 COBRA_TAK186: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (Also Known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients With Unresectable Locally Advanced or Metastatic Cancer
Ph 1/2,First-in-Human,Open-Label,Dose-Escalation Study TAK-186,A EGFRxCD3 Conditional Bispecific Redirected Activation (COBRA) Prot.in Pts w/Unresectable Local Adv/Mets Cancer
Takeda_TAK-280-1501: A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer
V940-007: A Phase 2/3, adaptive, randomized, open-label, clinical study to evaluate neoadjuvant and adjuvant V940 (mRNA-4157) in combination with pembrolizumab (MK- 3475) versus standard of care, and pembrolizumab monotherapy in participants with resectable locally advanced cutaneous squamous cell carcinoma (LA cSCC) (INTerpath-007)
Phase 2/3 adaptive randomized open-label neoadjuvant & adjuvant V940 (mRNA-4157) + pembrolizumab MK-3475 vs SOC & pembrolizumab alone in resectable LA cSCC INTerpath-007

Previous Next